NAA Associated Lung Cancer

Lung cancer (LC) is one of the most common malignant tumors and the leading cause of cancer death for both sexes worldwide. Few early detection tests or acceptable screening methods for this disease are available now. Therefore, it is necessary for us to develop more effective, non-invasive methods for the screening and early diagnosis of LC. As a well-recognized leader in disease diagnosis and with over decades of experience, Creative Biolabs is dedicated to developing serum natural autoantibodies (NAA) tests against autologous cellular antigens and offering you a comprehensive set of high-quality NAA services for LC.

Introduction of Lung Cancer

In most patients, LC is usually advanced at the time of diagnosis, with 5-year survival rates vary from 4-17% depending on the stage and regional differences. The most common cause of LC is the prolonged exposure to tobacco smoke, which is the reason for 90% of lung cancers. The percent of LC in people who do not smoke is 10% and the reason is often due to a combination of other factors including genetic factors, radon gas, asbestos, and air pollution such as cigarette smoke of another person. Early detection of LC can be achieved by analysis of biomarkers from tissue samples within the respiratory tract such as sputum, saliva, nasal/bronchial airway epithelial cells, and exhaled breath condensate or through peripheral body fluids such as blood, serum, and urine. Recent years, evidence has demonstrated the potential diagnostic values of NAA and their application as biomarkers for LC. Moreover, a panel of assays for NAA with various TAA specificities can effectively detect LC because of the heterogeneity of single antigen expression.

Fig.1 Lung cancer types. (Sánchez-Ortega, Ana and Antonio, 2021)Fig.1 Classification of lung cancer.1

The Importance of NAA in the Diagnosis of Lung Cancer

Present diagnostic blood tests focus on detecting tumor-associated antigen (TAA) markers which show an increased positivity at advanced stages but are rarely used as early biomarkers because of their low sensitivity and specificity. Blood tests of serum tumor-associated autoantibodies (TAAbs) against overexpressed, mutated, misfolded, or aberrant autologous cellular antigens produced by cancer cells, may identify individuals with early LC and distinguish high-risk smokers with benign nodules from those with LC. NAAs to TAAs may persist in the circulating blood longer than the autoantigens themselves, and maybe more easily detected and have the potential to become highly useful diagnostic markers in a variety of cancers, including LC. Besides, it is reported that combinations of serum single or multiplex TAAs may be useful for discriminating LC patients at all stages or an early-stage from healthy controls or benign diseases, but the combination of multiplex autoantibodies shows a higher detection capacity. Here show several targets in LC that have already been developed to offer services by us.

Natural Autoantibodies Targets in Lung Cancer
Anti-p53 Anti-CAGE Anti-MUC1 Anti-GM-CSF
Anti-c-Myc Anti-GBU4-5 Anti-HER2 Anti-NY-ESO-1

Early detection and immediate initiation of treatment are now considered as the mainstay to reduce the mortality of LC. Equipped with advanced high-resolution analytical platforms and experienced technical personnel, the technical team at Creative Biolabs is fully competent and dedicated to serving as your one-stop-shop for NAA analysis and characterizations. Please do not hesitate to contact us for more information and a detailed quote, if the disease and related targets you interested is not mentioned above.

Reference

  1. Sánchez-Ortega, Miriam, Ana Clara Carrera, and Antonio Garrido. "Role of NRF2 in lung cancer." Cells 10.8 (2021): 1879.

Choosing natural autoantibody (NAA) microarray to profile autoantibody repertoire and reveal novel disease's marker.

For Research Use Only | Not For Clinical Use

Related Services:

Products:

Resource:

Applications:

Online Inquiry
Inquiry